Sensus Healthcare (NASDAQ: SRTS) reported Q2 2026 revenue of $2.3 million, down 68.5% from $7.3 million a year earlier, while diluted loss per share widened to $0.53 from $0.06. Lower unit volume and delayed revenue recognition weighed on the quarter, while a $5.7 million deferred-tax valuation allowance substantially increased the GAAP net loss.

Core financial results

Revenue fell as Sensus reported 11 units, including Fair Deal Agreement placements and rentals, compared with 19 units in Q2 2025. The company also recorded no sales to a historically large customer, while financing approval timing shifted revenue from eight units into Q3.

Lower operating expenses were not enough to offset the decline in gross profit. Gross margin contracted because international shipments carried lower average selling prices and costs for Fair Deal Agreement placements were recognized upfront while the associated revenue will be recognized over the agreement term.

Adjusted EBITDA is a non-GAAP measure that excludes interest, taxes, depreciation, amortization and stock-based compensation.

Business and commercial performance

Reported unit volume weakened, but management said commercial engagement and the sales pipeline improved following the implementation of dedicated CPT codes. The company expanded its work with independent practices, larger physician groups and health systems, while active website users increased 153% year over year.

Management said the eight units affected by financing approvals were subsequently sold and that the related revenue would be recognized in Q3. The delay therefore shifted the timing of revenue rather than canceling the transactions, although the company did not disclose the amount of revenue involved.

Sensus also increased its use of Fair Deal Agreements and rental arrangements. These models spread revenue over the agreement term rather than recognizing it when a system is shipped, creating a different reported revenue pattern from outright system sales.

International commercial activity expanded in Australia and New Zealand. However, the higher proportion of international shipments in Q2 contributed to lower gross margin because those systems carried lower average selling prices.

CMS proposed a 26% increase in the hospital-based SRT delivery code. If finalized, the change could improve provider economics in hospitals and health systems, but it remained a proposal at the time of the earnings release.

A tax valuation allowance amplified the operating loss

Sensus recorded a $3.1 million pre-tax loss but an $8.7 million GAAP net loss. The difference primarily reflected a $5.7 million valuation allowance against net deferred-tax assets, recorded as income-tax expense during the quarter.

The tax charge explains much of the sharp deterioration in GAAP EPS, but operating performance also weakened. Adjusted EBITDA declined to negative $3.0 million from negative $1.8 million as the reduction in gross profit outweighed lower operating expenses.

Profitability, liquidity and the balance sheet

Sensus reduced spending across each major operating-expense category. General and administrative expense declined 10.0% to $1.8 million, selling and marketing expense fell 21.4% to $1.1 million, and research and development expense decreased 26.7% to $1.1 million. The reductions reflected lower compensation, trade-show and commission costs, reduced clinical research spending, lower next-generation system development costs and reduced headcount.

Cash, restricted cash and cash equivalents stood at $15.2 million on June 30, down approximately $3.1 million from March 31. The company had no outstanding borrowings under its revolving credit line.

Inventory increased to $18.5 million from $16.5 million at the end of March, while prepaid inventory declined to $0.6 million from $2.5 million. The combination of a lower cash balance, higher inventory and continuing operating losses makes liquidity and inventory conversion important measures for subsequent quarters.

Management perspective

Chairman and CEO Joseph Sardano characterized the financing delay as a revenue-recognition timing issue rather than a sign of weaker customer demand. Management pointed to higher physician engagement, broader relationships with physician groups, increased Fair Deal Agreement utilization and expansion in Asia-Pacific markets as evidence of commercial progress.

The company remains focused on stronger second-half performance and identified education and training, customer adoption, recurring revenue, commercial expansion and progress toward profitability as its five strategic priorities. It did not provide quantitative revenue or earnings guidance.

Risks investors should monitor

• Customer and unit-sales concentration: Q2 revenue was affected by the absence of sales to a historically large customer, highlighting the potential impact of individual customers and system orders on quarterly results.
• Financing and revenue-recognition timing: Customer financing approvals can move meaningful system revenue between quarters, while Fair Deal and rental contracts recognize revenue over time.
• Margin pressure from placement models and international mix: Fair Deal placement costs are recognized upfront, and international systems carry lower average selling prices, both of which can weigh on near-term gross margin.
• Liquidity and inventory: Cash declined during the quarter while inventory increased, and adjusted EBITDA remained negative.
• Reimbursement uncertainty: The proposed 26% increase in the hospital-based delivery code could support adoption if finalized, but reimbursement levels remain an important factor in providers’ purchasing decisions.

Summary

Sensus Healthcare’s Q2 2026 results reflected lower unit sales, revenue shifted into Q3 and accounting pressure from Fair Deal placements, producing a steep revenue decline and weaker gross margin. Expense reductions provided only a partial offset, while the deferred-tax valuation allowance drove a much larger GAAP net loss. The next quarter will show whether recognition of the eight delayed units and management’s reported pipeline momentum can improve revenue without placing further pressure on margin and liquidity.

Find out more